Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 8,241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Completed Phase 1 Interventional

Imaging With a New Agent That Finds a Cancer Protein Called HER2

NCT03109977
View directory record Official record
Conditions
HER2-positive Carcinoma, HER2-positive Primary Malignancy
Interventions
Zr-DFO-pertuzumab PET/CT
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 23, 2026, 8:08 AM EDT
Not listed Phase 1Phase 2 Interventional

ALG.APV-527 First-in-human Study

NCT05934539
View directory record Official record
Conditions
Solid Tumor
Interventions
ALG.APV-527
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 23, 2026, 8:08 AM EDT
Terminated Not applicable Interventional

Treatment of Chronic Cryptosporidiosis in AIDS Patients

NCT00001128
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Interleukin-12, Paromomycin sulfate, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 2 Interventional

A Study in a Human Laboratory Model of Smoking Behavior

NCT02641028
View directory record Official record
Conditions
Smoking
Interventions
CERC-501, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
21 Years to 60 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Overland Park, Kansas • Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Candin Safety & Efficacy Study for the Treatment of Warts

NCT01757392
View directory record Official record
Conditions
Warts, Human Papilloma Virus
Interventions
Candida albicans Skin Test Antigen
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Fort Smith, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA

NCT00334607
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
2-dose oral live attenuated G1P[8] human rotavirus vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 16 Weeks
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Benton, Arkansas • Cabot, Arkansas • Jonesboro, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 23, 2026, 8:08 AM EDT
Withdrawn Phase 4 Interventional

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

NCT03093740
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
Zepatier, Zepatier plus Sofosbuvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00633750
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, TUNEL assay, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, matrix-assisted laser desorption ionization mass spectrometry, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms Defending Fat Mass in Humans After Lipectomy

NCT00993213
View directory record Official record
Conditions
Disproportionate Shape, Expanded Fat Pads
Interventions
Standard of Care with Liposuction, Standard of Care without Liposuction
Procedure · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

NCT02579382
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, Vesatolimod, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Reanimation in Tetraplegia

NCT01997125
View directory record Official record
Conditions
Spinal Cord Injury (Quadraplegia)
Interventions
Neural Bridge System
Device
Lead sponsor
Marcia Bockbrader
Other
Eligibility
21 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 23, 2026, 8:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

NCT05875168
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
DS-3939a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Sarasota, Florida • Locust Grove, Georgia • Westwood, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics

NCT02177513
View directory record Official record
Conditions
Cannabis Use
Interventions
Placebo + Placebo, Oral Cannabis + Placebo, Placebo + Inhaled Cannabis, Placebo + Smoked Cannabis, 6.9% cannabis oral
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 23, 2026, 8:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Apple Respiratory Study

NCT04912180
View directory record Official record
Conditions
Acute Respiratory Infection, Coronavirus Infection, Influenza
Interventions
Not listed
Lead sponsor
Apple Inc.
Industry
Eligibility
22 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 23, 2026, 8:08 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of An Oral Fluid Collection Device

NCT02026440
View directory record Official record
Conditions
Smoking
Interventions
Not listed
Lead sponsor
Avioq, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2014 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community Pharmacists Vaccinate Against Cancer

NCT04072159
View directory record Official record
Conditions
Human Papillomavirus Vaccines
Interventions
Community Pharmacists Vaccinating Against Cancer
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-323 in Healthy Subjects

NCT05587478
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-323, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 23, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840
View directory record Official record
Conditions
Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions
Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
Dietary Supplement
Lead sponsor
Quantec Ltd
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
25
States / cities
Bakersfield, California • Pasadena, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

NCT00264576
View directory record Official record
Conditions
Influenza Disease; Flu
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

NCT00764790
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, Fluzone
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 23, 2026, 8:08 AM EDT
Completed Phase 4 Interventional

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

NCT00575224
View directory record Official record
Conditions
Chronic Hepatitis C, Asian Americans, Novel Genotypes, Treatment
Interventions
Pegylated interferon and ribavirin
Drug
Lead sponsor
Pacific Health Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
San Diego, California • San Jose, California • Westminster, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 23, 2026, 8:08 AM EDT